以岭药业品牌怎么样 申请店铺

我要投票 以岭药业在中草药行业中的票数:40 更新时间:2024-12-27
以岭药业是哪个国家的品牌?「以岭药业」是 石家庄以岭药业股份有限公司 旗下著名品牌。该品牌发源于河北,由创始人吴相君在2001期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
以岭药业怎么样

国家重点高新技术企业--石家庄以岭药业股份有限公司由中国工程院吴以岭院士创建,在他的领导下,以岭药业始终坚持以科技为先导,以市场为龙头的科技创新发展战略,创立"理论-科研-新药-生产-营销"五位一体的独特运营模式,建立起以中医络病理论创新为指导的新药研发创新技术体系。

在以岭药业的发展历程中,凝聚了一大批科研、管理、生产、营销精英,包括归国专家、外籍专家、博士、硕士及各类高职人才,为河北医科大学培养博士、硕士研究生,被国家人事部批准为博士后科研工作站。

以岭药业以络病理论创新带动中医药产业化,运用现代高新技术研发现代中药、西药、和生物药,研发国家专利新药9个,覆盖心脑血管疾病、感冒呼吸疾病、肿瘤、糖尿病及其并发症等重大疾病领域。通过国家GMP认证的中药生产线、通过欧盟认证的化学制剂生产车间具有年产值达50亿的生产能力。以岭药业为国家创新型企业、中国制药工业50强,以岭商标成为中国驰名商标。

国家科技部前领导曾赞誉五位一体的发展模式为"我国中医药科技成果产业化的创举"。

以岭药业立足国内、接轨国际,在石家庄、北京大兴、密云建立了三个国际标准的科研生产基地,通过了欧盟、新西兰等GMP认证。科研、生产、质检、贸易、管理人才全部具有国际化背景,构建了符合国际药品标准的生产、质控体系。依靠现代高新技术与设备和完善的药品生产质量控制体系,生产高品质中药与西药。产品已经出口到英国、美国、西班牙、韩国、日本、俄罗斯、新西兰等许多国家。

位于北京生物工程与医药产业基地的北京以岭药业,占地210亩,为国家重点高新技术企业,主要生产面向国际市场的植物药、保健品、膳食补充剂。

位于北京密云的北京以岭生物按照欧美GMP标准建设,主要生产面向国际市场的激素、肿瘤类药物和具有自主知识产权的新制剂。

Shijiazhuang Yiling Pharmaceutical Co., Ltd, a national key high-tech enterprise, was founded by Academician Wu Yiling of Chinese Academy of engineering. Under his leadership, Yiling pharmaceutical always adheres to the development strategy of scientific and technological innovation with science and technology as the guide and market as the leader, creates a unique operation mode of "theory research new medicine production marketing" and establishes a theoretical innovation of traditional Chinese medicine collateral disease as the reference New drug R & D innovation technology system. In the development process of Yiling pharmaceutical industry, a large number of scientific research, management, production and marketing elites, including returned experts, foreign experts, doctors, masters and all kinds of higher vocational talents, have been gathered, training doctors and masters for Hebei Medical University, and approved by the Ministry of human resources as post doctoral research workstation. Lingyao promotes the industrialization of traditional Chinese medicine with the innovation of collateral disease theory, develops modern Chinese medicine, western medicine and biological medicine with modern high and new technology, and develops 9 new national patent drugs, covering the major disease fields such as cardio cerebrovascular disease, cold and respiratory disease, tumor, diabetes and its complications. The production line of traditional Chinese medicine certified by national GMP and the chemical production workshop certified by European Union have an annual output value of 5 billion. Take Ling pharmaceutical as a national innovative enterprise and top 50 pharmaceutical industry in China, and take Ling trademark as a well-known trademark in China. Former leaders of the Ministry of science and technology of the people's Republic of China once praised the five in one development mode as "the pioneering work of industrialization of scientific and technological achievements of traditional Chinese medicine". Based on domestic and international standards, Yiling pharmaceutical has established three international standard research and production bases in Shijiazhuang, Beijing Daxing and Miyun, and has passed GMP certification of EU, New Zealand, etc. The talents of scientific research, production, quality inspection, trade and management all have international background, and the production and quality control system in line with international drug standards has been established. Relying on modern high-tech and equipment and perfect quality control system of drug production, we can produce high-quality traditional Chinese medicine and Western medicine. The products have been exported to the United Kingdom, the United States, Spain, South Korea, Japan, Russia, New Zealand and many other countries. Located in Beijing bioengineering and pharmaceutical industry base, Beijing Yiling pharmaceutical, covering an area of 210 mu, is a national key high-tech enterprise, which mainly produces plant medicine, health care products and dietary supplements for the international market. Beijing Yiling biology, located in Miyun, Beijing, is built in accordance with European and American GMP standards. It mainly produces hormones, tumor drugs and new preparations with independent intellectual property rights for the international market.

本文链接: https://brand.waitui.com/887854f10.html 联系电话:0311-87320288

千城特选小程序码

7×24h 快讯

沪深两市成交额连续第63个交易日突破1万亿

36氪获悉,沪深两市成交额连续第63个交易日突破1万亿,较上日此时放量近1100亿。

25分钟前

日本政府通过温室气体减排新目标:2035年度较2013年度减排60%

据报道,日本政府12月27日召开全球变暖对策推进总部(总部长:首相石破茂)会议,通过了全球变暖对策计划的修改方案,其中提出“2035年度较2013年度减排60%、2040年度减排73%”的温室气体减排新目标。日本政府将在征求公众意见后,在内阁会议上敲定修改方案,并力争在2025年2月底前向联合国汇报。(界面)

25分钟前

南京公用宣布并购,股价“提前”涨停,公司最新回应

26日晚间,南京公用公告,公司拟购买宇谷科技约68%股权并募集配套资金。本次交易预计不构成重大资产重组,不构成重组上市。公司股票自12月27日开市起停牌,预计不超过10个交易日。公告当日,该股录得涨停。对此,南京公用相关人士表示,公司主营能源业务,以传统燃气为主。同时也在布局新能源领域,包括充电桩业务等,不过体量尚小。目前相关事宜处于初步商谈阶段,后续情况以公司公告为准。关于股价“提前”涨停,前述人士表示,公司股价近期涨跌频繁,不清楚昨日涨停原因。交易双方不存在内幕消息泄露的情形。(21财经)

25分钟前

力箭一号遥六民营商业运载火箭飞行试验任务失利

12月27日9时3分,力箭一号遥六民营商业运载火箭在东风商业航天创新试验区点火升空,火箭飞行异常,飞行试验任务失利。具体原因正在进一步分析排查。(新华社)

25分钟前

韩国央行:超三成韩国人持有加密货币

韩国央行根据在Upbit、Bithumb、Coin One、Cobit和Gopax等五大韩国交易所拥有账户的投资者数量统计发布报告称,截至今年11月,在韩国交易所持有加密货币的人数超过1559万人,比10月份的1498万人增加了61万人。目前,韩国总人口预计在5123万人左右。这意味着,持有加密货币的人口数量相当于总人口的30%以上。报告称,韩国加密货币投资者的数量一直在上升,而在11月更是直线飙升。(财联社)

25分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询